Covid-19 might provide a fast road to market for the company. Given the high
medical need for a treatment for Covid-19, bemcentinib could reach the market quickly
– if it is successful in initial trials. Penetration would depend on clinical outcomes and
pricing, but we believe BerGenBio could price it relatively high (cUSD2,340 for a 7-day
treatment) without cannibalising on its use in future cancer indications.
Skal være fra DNB